A bill codifying the US Food and Drug Administration’s current approach to determining new chemical entity exclusivity appears to give the agency leeway to make future changes in how it defines potentially eligible drug products, legal experts said.
The Ensuring Innovation Act (S. 415) was signed by President Joe Biden on 23 April after passing the Senate...







